Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT03972345

Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)

Participants are free to decide if they want to take part in this study or not. The study will be conducted to collect information about the influence of adherence to growth hormone therapy with Norditropin® in children and teenagers in daily practice in Germany. This study will look mainly at the difference in near final height between children and teenagers who adhere to their therapy plan with Norditropin® to non-adherent patients. Participants will get Norditropin® as prescribed to them by their doctor. The study will last as long as the therapy with growth hormone is seen necessary by the participants' doctors and the participants, up to a maximum of 10 years. During the visits at the participants' doctors participants will be asked to fill in a questionnaire.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Growth Hormone Deficiency in Children Born Small for Gestational Age

Age range

0 year–15 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Uniklinik Ulm - Dt. Zentrum für Kinder- und Jugendgesundheit (DZKJ)

Ulm, 89075, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent of parent or legally acceptable representative of subject and child assent, as age-appropriate must be obtained before any study-related activities.
  • The parent or legally acceptable representative of the child must sign and date the Informed Consent Form (according to local requirements) and
  • The child must sign and date the Child Assent Form or provide oral assent (if required according to local requirements).
  • The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
  • Male or female, all age groups equal to or below 15 years with more than 2 years expected remaining treatment time until reaching NFH. Patients who self-inject should be above 8 years of age in order to be able to fill in the questionnaire.
  • Children being GH naïve at baseline with one of the following confirmed diagnoses
  • Isolated growth hormone deficiency (iGHD)
  • Small for gestational age (SGA)

Exclusion criteria

  • Previous participation in this study. Participation is defined as having given informed consent in this study.
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
  • Patients who have an expected future duration of therapy of less than 2 years are not eligible for the study.

Treatment and study plan

Norditropin® FlexPro®

Drug

Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.

Primary outcomes

  1. Near final height (NFH) standard deviation score (SDS) measured in scores

    Time frame: At the end of the study (up to 10 years)

    SDS, -3 to +3

Secondary outcomes

  1. Change in growth rate (height velocity standard deviation score, HV SDS)

    Time frame: From baseline (month 0) to end of study (up to 10 years)

    Score, range -10 to +10

  2. Change in growth rate (HV SDS) between visits (usually patients are seen every 3 to 6 months)

    Time frame: From baseline (month 0) to end of study (up to 10 years)

    Score, range -10 to +10

  3. Adherence response as indicated in question at the bottom of newly developed Patient Reported Outcome (PRO) questionnaire each time questionnaire is filled out (preferably at each visit)

    Time frame: From baseline (month 0) to end of study (up to 10 years)

    The following adherence levels will be used:

    High adherence: above 85.7% of doses administered Medium adherence: 57.1 - 85.7% of doses administered Low adherence: below 57.1% of doses administered

  4. Adherence measured as number of medication devices returned versus number of prescribed devices for the period between visits

    Time frame: From baseline (month 0) to end of study (up to 10 years)

    Count

  5. Change of self-rated adherence level throughout the study measured in newly developed PRO questionnaire each time questionnaire is filled out (preferably at each visit)

    Time frame: From baseline (month 0) to end of study (up to 10 years)

    The following adherence levels will be used:

    High adherence: above 85.7% of doses administered Medium adherence: 57.1 - 85.7% of doses administered Low adherence: below 57.1% of doses administered

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

A Non-interventional, Prospective Study in Germany to Investigate the Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in a Patient Population With Isolated Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)

Important dates

Study start
2019
Primary completion
2029
Study completion
2031
First posted
Jun 3, 2019
Registry last updated
Sep 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.